Literature DB >> 8710921

Characterization of the osmotic response element of the human aldose reductase gene promoter.

B Ruepp1, K M Bohren, K H Gabbay.   

Abstract

Aldose reductase (EC 1.1.1.21) catalyzes the NADPH-mediated conversion of glucose to sorbitol. The hyperglycemia of diabetes increases sorbitol production primarily through substrate availability and is thought to contribute to the pathogenesis of many diabetic complications. Increased sorbitol production can also occur at normoglycemic levels via rapid increases in aldose reductase transcription and expression, which have been shown to occur upon exposure of many cell types to hyperosmotic conditions. The induction of aldose reductase transcription and the accumulation of sorbitol, an organic osmolyte, have been shown to be part of the physiological osmoregulatory mechanism whereby renal tubular cells adjust to the intraluminal hyperosmolality during urinary concentration. Previously, to explore the mechanism regulating aldose reductase levels, we partially characterized the human aldose reductase gene promoter present in a 4.2-kb fragment upstream of the transcription initiation start site. A fragment (-192 to +31 bp) was shown to contain several elements that control the basal expression of the enzyme. In this study, we examined the entire 4.2-kb human AR gene promoter fragment by deletion mutagenesis and transfection studies for the presence of osmotic response enhancer elements. An 11-bp nucleotide sequence (TGGAAAATTAC) was located 3.7 kb upstream of the transcription initiation site that mediates hypertonicity-responsive enhancer activity. This osmotic response element (ORE) increased the expression of the chloramphenicol acetyltransferase reporter gene product 2-fold in transfected HepG2 cells exposed to hypertonic NaCl media as compared with isoosmotic media. A more distal homologous sequence is also described; however, this sequence has no osmotic enhancer activity in transfected cells. Specific ORE mutant constructs, gel shift, and DNA fragment competition studies confirm the nature of the element and identify specific nucleotides essential for enhancer activity. A plasmid construct containing three repeat OREs and a heterologous promoter increased expression 8-fold in isoosmotic media and an additional 4-fold when the transfected cells are subjected to hyperosmotic stress (total approximately 30-fold). These findings will permit future studies to identify the transcription factors involved in the normal regulatory response mechanism to hypertonicity and to identify whether and how this response is altered in a variety of pathologic states, including diabetes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710921      PMCID: PMC38723          DOI: 10.1073/pnas.93.16.8624

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.

Authors:  A Beyer-Mears; E Cruz; T Edelist; E Varagiannis
Journal:  Pharmacology       Date:  1986       Impact factor: 2.547

Review 2.  The sorbitol pathway and the complications of diabetes.

Authors:  K H Gabbay
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

3.  Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin.

Authors:  S J Degen; R T MacGillivray; E W Davie
Journal:  Biochemistry       Date:  1983-04-26       Impact factor: 3.162

4.  Eukaryotic gene transcription with purified components.

Authors:  J D Dignam; P L Martin; B S Shastry; R G Roeder
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Depletion of myo-inositol and amino acids in galactosemic neuropathy.

Authors:  C Nishimura; M F Lou; J H Kinoshita
Journal:  J Neurochem       Date:  1987-07       Impact factor: 5.372

6.  Induction of aldose reductase and sorbitol in renal inner medullary cells by elevated extracellular NaCl.

Authors:  S M Bagnasco; S Uchida; R S Balaban; P F Kador; M B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

7.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

8.  Purification and characterization of human-brain aldose reductase.

Authors:  B Wermuth; H Bürgisser; K Bohren; J P von Wartburg
Journal:  Eur J Biochem       Date:  1982-10

9.  Firefly luciferase gene: structure and expression in mammalian cells.

Authors:  J R de Wet; K V Wood; M DeLuca; D R Helinski; S Subramani
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

10.  The canine betaine gamma-amino-n-butyric acid transporter gene: diverse mRNA isoforms are regulated by hypertonicity and are expressed in a tissue-specific manner.

Authors:  M Takenaka; S M Bagnasco; A S Preston; S Uchida; A Yamauchi; H M Kwon; J S Handler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more
  16 in total

1.  Osmolality/salinity-responsive enhancers (OSREs) control induction of osmoprotective genes in euryhaline fish.

Authors:  Xiaodan Wang; Dietmar Kültz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-13       Impact factor: 11.205

2.  Effects of exogenous desmopressin on a model of heat stress nephropathy in mice.

Authors:  Carlos A Roncal-Jimenez; Tamara Milagres; Ana Andres-Hernando; Masanari Kuwabara; Thomas Jensen; Zhilin Song; Petter Bjornstad; Gabriela E Garcia; Yuka Sato; Laura G Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-21

3.  Differential control of murine aldose reductase and fibroblast growth factor (FGF)-regulated-1 gene expression in NIH 3T3 cells by FGF-1 treatment and hyperosmotic stress.

Authors:  D K Hsu; Y Guo; K A Peifley; J A Winkles
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

4.  Fat-specific protein 27 modulates nuclear factor of activated T cells 5 and the cellular response to stress.

Authors:  Masami Ueno; Wen-Jun Shen; Shailja Patel; Andrew S Greenberg; Salman Azhar; Fredric B Kraemer
Journal:  J Lipid Res       Date:  2012-12-11       Impact factor: 5.922

5.  Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.

Authors:  H L Rittner; V Hafner; P A Klimiuk; L I Szweda; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

6.  Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.

Authors:  Laura G Sanchez-Lozada; Ana Andres-Hernando; Fernando E Garcia-Arroyo; Christina Cicerchi; Nanxing Li; Masanari Kuwabara; Carlos A Roncal-Jimenez; Richard J Johnson; Miguel A Lanaspa
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

7.  Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.

Authors:  T O'connor; L S Ireland; D J Harrison; J D Hayes
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

8.  Osmotic expression of aldose reductase in retinal pigment epithelial cells: involvement of NFAT5.

Authors:  Anica Winges; Tarcyane Barata Garcia; Philipp Prager; Peter Wiedemann; Leon Kohen; Andreas Bringmann; Margrit Hollborn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-14       Impact factor: 3.117

9.  Prostaglandin E2 stimulates expression of osmoprotective genes in MDCK cells and promotes survival under hypertonic conditions.

Authors:  Wolfgang Neuhofer; Daniela Steinert; Maria-Luisa Fraek; Franz-X Beck
Journal:  J Physiol       Date:  2007-06-07       Impact factor: 5.182

10.  Role of NFAT5 in inflammatory disorders associated with osmotic stress.

Authors:  Wolfgang Neuhofer
Journal:  Curr Genomics       Date:  2010-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.